Collegium Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Collegium Pharmaceutical has a total shareholder equity of $234.3M and total debt of $867.2M, which brings its debt-to-equity ratio to 370.2%. Its total assets and total liabilities are $1.6B and $1.4B respectively. Collegium Pharmaceutical's EBIT is $217.7M making its interest coverage ratio 4. It has cash and short-term investments of $145.0M.
Key information
370.2%
Debt to equity ratio
US$867.21m
Debt
| Interest coverage ratio | 4x |
| Cash | US$144.96m |
| Equity | US$234.28m |
| Total liabilities | US$1.40b |
| Total assets | US$1.64b |
Recent financial health updates
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Oct 28
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Recent updates
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality
Nov 14Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Oct 28Collegium Pharmaceutical: Diversifying And Growing
Aug 09Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking
Jul 24Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Collegium Pharmaceutical: Oversold And Cheap
Jun 12Financial Position Analysis
Short Term Liabilities: COLL's short term assets ($443.8M) do not cover its short term liabilities ($459.4M).
Long Term Liabilities: COLL's short term assets ($443.8M) do not cover its long term liabilities ($941.4M).
Debt to Equity History and Analysis
Debt Level: COLL's net debt to equity ratio (308.3%) is considered high.
Reducing Debt: COLL's debt to equity ratio has increased from 13.6% to 370.2% over the past 5 years.
Debt Coverage: COLL's debt is well covered by operating cash flow (22.3%).
Interest Coverage: COLL's interest payments on its debt are well covered by EBIT (4x coverage).